Best of 2022: Allopurinol Safety in CKD Patients https://t.co/BDjuL2Fp94 https://t.co/d3Jo4SKwHQ

• https://bit.ly/3WTEX2W

FDG-PET Scan in RA? Study of 34 #RA pts shows PET uptake (SUV scores) measures were significantly correlated with the number of swollen joints, SDAID but not the CDAI, disease duration, seropositivity, or RA treatments. https://t.co/AkGhEiNqwt https://t.co/FkKh49KYyd

• https://bit.ly/3WHhYbF

10% of PsA is PsA Sine Psoriasis - how to differentiate from seroneg RA? PsA sine PsO pts have peripheral arthritis, no skin dz, but may have axial sxs, +Family Hx or nail psoriasis, dactylitis, enthesitis, DIP involvement. https://t.co/BeYOq8ysgW https://t.co/pLogz1HHTV

• https://bit.ly/3FEeU8Y

IL-18 is a proinflammatory cytokine involved in innate & adaptive immune responses. IL-18 is a key mediator in autoinflammatory diseases, MAS, Still’s disease. Serum IL-18 levels may be useful in diagnosis and monitoring of disease activity https://t.co/1SXlODZcXc https://t.co/xtauaMMMos

• https://bit.ly/3PFBxyv

Does Methotrexate Use Lead to Melanoma? A systematic review suggests that low-dose methotrexate (MTX) use is associated with an increased melanoma risk, but the absolute risk increase could be considered negligible. https://t.co/dChsIsCAMt https://t.co/5PgjlunTmp

• https://bit.ly/3G3fmyY

Drugs causing Scleroderma (DASSc) - Anticancer rx made up 42% DASSc & 62.3% case reports. Included: taxane-based agents, bleomycin, vinblastine, imatinib, dacarbazine, pembrolizumab pemetrexed; also HRT romiplostim & eculizumab https://t.co/jPNIuaYdnJ https://t.co/efZG5kG2Yd

• https://bit.ly/3jdcpTx

2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/zjxZtTFnlS https://t.co/XTwip2wv1n

• https://bit.ly/3HWpPgS

Rituximab Efficacy in Systemic Sclerosis The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase. https://t.co/cqlVo104Y9 https://t.co/dYgBsj65BJ

• https://bit.ly/3jehET8

AVOID THE WEEKEND! Study of high-impact rheumatology journals (Rheumatology, J Rheum, & Seminars A&R) shows higher risk of "desk rejections" by editor (avoiding peer review) for manuscripts submitted Saturday (OR 1.23) or Sunday (OR 1.13) https://t.co/rWIkiYgh8Y https://t.co/kPSJmfWSUl

• https://bit.ly/3Yxly9D

Treatment of pyoderma gangrenosum is clinically empiric. Full read ref w/ Graded Rx Recommendations: - 1st line: Steriods or Cyclosporin - Consider biologics: TNFi, IL-1, IL-12/23, IL-17, IL-23 - Others: MTX, MMF, AZA, Dap, colchic, thalidomide, IVIG https://t.co/z0XeT0ja45 https://t.co/fWAcryIDJR

• https://bit.ly/3hAn8XR

Women Heroes in Rheum: - Barbara Ansell - JIA - Nanna Svartz - SSZ - Gertrude Elion - Nobel Prize for allopurinol, AZA - Tsai-Fan Yu - gout Rx - Mary Betty Stevens - lupus & vasculitis - Marian Ropes - 1st F ARA president - Fionula Brennan - TNFi & more https://t.co/FDRORJ7c1q https://t.co/ZebVagIyQA

• https://bit.ly/3YMYBzF

Best of 2022: Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines https://t.co/Swf5kq6VtG https://t.co/UTIaCFpAX6

• https://bit.ly/3Wxs12S

Good review of Diagnosis and Treatment of Pulmonary Sarcoidosis in JAMA. - Lung progression (in only 10%) assoc w/ 12-18% 5yr mortality - Sx Sarcoid w/ Lung: start Pred 20 to 40 mg/d for 2 -6 wks - Steroid sparing w/ MTX, AZA or TNFi https://t.co/aVnUXaj0sj https://t.co/JN142hlR6g

• https://bit.ly/3PBwYFn

Approximately 61% of patients with rheumatoid arthritis or psoriatic arthritis who use methotrexate report side effects following weekly dosing, including fatigue and nausea, according to data published in Rheumatology and Therapy https://t.co/k7hhdbIhW1 https://t.co/GiaihMGnWK

• https://bit.ly/3FDWYv5

Full read review of advances in bone biology leading to drug development (denosumab, romosuzumab, Burosumab), advances in Pagets and rickets and key regulatory molecules for bone remodeling, RANK, RANKL, OPG, & sclerostin https://t.co/1d6A6MsdbJ https://t.co/IuKEp1PQtr

• https://bit.ly/3HNCHGn